Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Ryoichi Shiroki, Yusuke Yano et al.|Clinical Genitourinary Cancer|2023Cited by 8
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Takahiro Kimura, Keiichiro Mori et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 7